OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
73
Results
Show all
Save search
Copy query
Show results for
Unknown
(43)
Transcriptomics
(24)
Proteomics
(5)
Metabolomics
(1)
Organisms
Mus musculus
(9)
Homo sapiens
(6)
Solea senegalensis
(5)
Danio rerio
(2)
Oncorhynchus mykiss
(1)
Rattus norvegicus
(1)
Drosophila melanogaster
(1)
Repository
biostudies-arrayexpress
(24)
MassIVE
(4)
MetaboLights
(1)
pride
(1)
Technology Type
Mass spectrometry
(1)
Mass Spectrometry
(1)
Shotgun proteomics
(1)
Instrument Platform
Q Exactive
(2)
LTQ Orbitrap Elite
(1)
Q Exactive HF-X
(1)
TripleTOF 5600
(1)
Liquid Chromatography MS - positive - reverse phase
(1)
Publication Date
2010
(14)
2012
(2)
2008
(2)
2007
(2)
2019
(2)
2014
(1)
2013
(1)
2011
(1)
2005
(1)
2023
(1)
2017
(1)
2024
(1)
2022
(1)
Study type
Transcription profiling by array
(20)
Unknown experiment type
(1)
ChIP-chip by tiling array
(1)
Comparative genomic hybridization by array
(1)
Other
(1)
Release Date
2010
(14)
2023
(6)
2022
(6)
2021
(6)
2024
(5)
2019
(5)
2025
(4)
2011
(3)
2008
(3)
2018
(3)
2012
(2)
2007
(2)
2020
(2)
2014
(1)
2013
(1)
2005
(1)
2016
(1)
2015
(1)
2006
(1)
Lab affiliation
Technical University of Munich Department of Chemistry and Institute for Advanced Study Lichtenbergstr. 4 85748 Garching, Germany
(1)
Previous
page
1 / 8
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
8
Next
page
Sort
by:
Relevance
Page size
10
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Not available
S-EPMC10087094
|
biostudies-literature
Cite
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Not available
S-EPMC7042988
|
biostudies-literature
Cite
A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B.
Not available
S-EPMC9843052
|
biostudies-literature
Cite
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Not available
S-EPMC9204964
|
biostudies-literature
Cite
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Not available
S-EPMC10787703
|
biostudies-literature
Cite
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Not available
S-EPMC8570909
|
biostudies-literature
Cite
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Not available
S-EPMC10518480
|
biostudies-literature
Cite
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Not available
S-EPMC10442127
|
biostudies-literature
Cite
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Not available
S-EPMC11137442
|
biostudies-literature
Cite
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Not available
S-EPMC11561219
|
biostudies-literature
Cite
Previous
page
1 / 8
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
8
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
